TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06197984

Intervention type: PROCEDURE
Intervention: ERCP
Description: ERCP will serve as the exclusive therapeutic modality, aided by a therapeutic duodenoscope to access the common bile duct using a guidewire.
Study: NCT06419998

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A: Pure transanal endorectal pull-through (TAERPT)
Description: Patients of Group A will be treated totally by pure transanal endorectal pull-through without the assistance of laparoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B: Laparoscopic-assistance endorectal pull-through (LAERPT)
Description: Patients of Group B will be treated transanal endorectal pull-through but with the assistance of laparoscopy
Study: NCT05813756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-diagnosctic psychoeducational intervention
Description: Participants are randomized to the intervention group. In this group, the participant receives 10 one-hour individual sessions of psychoeducational intervention, bi-monthly, with an evaluation at mid-term (T1:T0+\~2.5 months), at the end of the intervention (T2 : T0+\~5 months) and 3 months after the intervention (T3 : T0+\~8 months). At the same time psychological questionnaires and scales will be completed
Study: NCT06263764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to Qur'an Recital
Description: Listening to Surah Ar Rahman twice a day for minimum 15 minutes each for 40 days
Study: NCT05714917

Intervention type: OTHER
Intervention: Observational study with no interventions
Description: This is an observational study and there will be no clinical interventions.
Study: NCT06370052

Intervention type: PROCEDURE
Intervention: excision
Description: excision of the affected area
Study: NCT06227052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Num Vapocoolant Spray
Description: This is the study arm. Partipants in this arm will receive Num vapocoolant spray during their gynecologic procedure. They will receive the spray on their cervix right before the paracervical block. Num Vapocoolant spray is currently FDA approved to be used on skin prior to injections. The investigators are using it in the same fashion but in the vagina on the cervix to help with the pain of the paracervical block injection.
Study: NCT05436990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, Vactosertib
Description: Participants will be treated for up to 35 cycles (approximately 2 years) after initiation of treatment with intravenous 200mg of pembrolizumab every 3 weeks in combination with vactosertib. Vactosertib will be given orally for 200mg, bid for 5 days (from Mon. to Fri.) per week.
Study: NCT06227052

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the placebo. This group will receive Natures tear normal saline spray.
Study: NCT06113887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation based on acceptance and commitment therapy
Description: Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation based on acceptance and commitment therapy
Description: Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation based on acceptance and commitment therapy
Description: Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation based on acceptance and commitment therapy
Description: Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation based on acceptance and commitment therapy
Description: Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation based on acceptance and commitment therapy
Description: Acceptance and Commitment Therapy Based Psychoeducation will be applied to the patients in the intervention group in the form of group education (consisting of 5-7 people), one session per week for eight weeks; no intervention will be applied to the control group.
Study: NCT06200129

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: sws grade 1
Description: Blood for zonulin level was drawn from the group of patients with typical white lesions in the duodenum, called grade 1.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: sws grade 2
Description: Blood for zonulin level was drawn from the group of patients with typical white lesions in the duodenum, called grade 2

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: control
Description: Group of patients without scattered white lesions in the dueodenum on endoscopy.
Study: NCT04916587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Strategy of ACEs Screenings
Description: We will use implementation mapping, guided by the EPIS framework, to promote a co-created process and refine the strategy comprised of online training videos, a customized ACEs algorithm and use of technology to improve workflow efficiency, implementation technical assistance/coaching, and written implementation protocols.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The ACEs Aware policy goal is to equip providers with training and clinical protocols to screen children and adults for ACEs, detect ACEs early, and connect patients to interventions, resources, and other support to improve patient health and well-being. ACEs screenings are comprised of: a) a 2-hour on-line provider training; b) the Pediatric ACEs and Related Life-events Screener or PEARLS tool; c) an ACEs associated health conditions checklist; and d) complete a wellness exam. The primary care provider uses multiple sources of information to identify a child's need for follow-up services.
Study: NCT05613387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP8396
Description: Part 1: Participants will receive 6 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort.~Part 2: Participants will receive 16 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort. Dose up-titration will be used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Placebo (ZP8396)
Description: Part 1: Participants will receive 6 once-weekly doses of placebo given subcutaneously (s.c., under the skin).~Part 2: Participants will receive 16 once-weekly doses of placebo given subcutaneously (s.c., under the skin).
Study: NCT06454994

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eyebrow lift
Description: Upper face lifting

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyebrow lift
Description: Upper face lifting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jaw lift
Description: Mid-face and low-face lifting

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jaw lift
Description: Mid-face and low-face lifting
Study: NCT05438563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-Guided Transurethral Ultrasound Ablation
Description: Undergo MRI-Guided TULSA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Rectal Examination
Description: Undergo DRE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: Undergo cystoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET Scan
Description: Undergo PSMA PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo mpMRI
Study: NCT05131269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 15 % in Water
Description: A 15% dextrose solution is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 20 mL Injection
Description: A Normal Saline 0.9% is given to shoulder segments four times with 2 weeks interval (week 0,2,4, and 6)
Study: NCT05017103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Given IV
Study: NCT04551404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial Random Noise Stimulation (tRNS) with acoustic stimulation (AS)
Description: The study intervention consists of a bilateral tRNS application over temporal regions, parallel to the application of AS with WN 15 dB above the individual MML in one study arm. TRNS will be applied using two electrodes (35 qcm, 0,9% saline -soaked). Stimulus intensity will be below individual sensation threshold, but max. 2 mA. AS will never surpass 85 dB SPL at the ears.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial Random Noise Stimulation (tRNS) without acoustic stimulation (AS)
Description: The study intervention consists of a bilateral tRNS application over temporal regions
Study: NCT05404724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole、 SHR0302 tablets
Description: Itraconazole 7 times and SHR0302 tablets twice. On the 8th day of this, itraconazole and SHR0302 tablets were taken simultaneously.
Study: NCT04821024

Intervention type: DIAGNOSTIC_TEST
Intervention: A self-administered questionnaire
Description: A self-administered questionnaire will be used to screen Neck disability index, demographic information and ergonomic risk factors.

Intervention type: DIAGNOSTIC_TEST
Intervention: A self-administered questionnaire
Description: A self-administered questionnaire will be used to screen Neck disability index, demographic information and ergonomic risk factors.
Study: NCT05557500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repitetive transcranial magnetic stimulation
Description: Repitetive transcranial magnetic stimulation on primary motor area with 20 HZ for 20 sessions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repitetive transcranial magnetic stimulation
Description: Repitetive transcranial magnetic stimulation on primary motor area with 20 HZ for 20 sessions
Study: NCT06311344

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Molecular biology analyses
Description: Samples of M. perstans microfilariae will be processed by PCR to investigate the presence (or absence) of Wolbachia using a set of primers targeting the genes ftsZ and 16S and optimized using reference material during the first year of the study. Samples of Schistosoma eggs from urine and feces will be processed for DNA extraction. Each sample will be genetically characterised by multi locus analysis of the mitochondrial cox1 region and the nuclear ITS and 18S rRNA regions. PCR products will be analysed by agarose gel electrophoresis and selected amplicons will be purified and Sanger sequenced. For the individuation of Schistosoma hybrids, the nuclear DNA for each sample will be confirmed by analysis of the species-specific polymorphic positions of the ITS1+2 and 18S. The mitochondrial and nuclear DNA genetic profiles for each individual sample will be recorded to determine the species involved in the infections and also any hybrid schistosomes
Study: NCT04927247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclacumab
Description: Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug.
Study: NCT05218070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EgyVax Vaccine Candidate
Description: EgyVax Inactivated SARS-CoV-2 vaccine candidate, equivalent to 70 mcg inactivated SARS-CoV-2 total protein. Alum adjuvant 2% 50 µl (equivalent to 0.5 mg AlOH). Equivalent volume of Saline 0.9% to each vaccine dose. Each vial contains 0.5 ml representing one dose 70 mcg of inactivated SARS-CoV-2 virus with alum adjuvant or two doses of 35 mcg of inactivated SARS-CoV-2 virus with alum adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EgyVax Vaccine Candidate
Description: EgyVax Inactivated SARS-CoV-2 vaccine candidate, equivalent to 70 mcg inactivated SARS-CoV-2 total protein. Alum adjuvant 2% 50 µl (equivalent to 0.5 mg AlOH). Equivalent volume of Saline 0.9% to each vaccine dose. Each vial contains 0.5 ml representing one dose 70 mcg of inactivated SARS-CoV-2 virus with alum adjuvant or two doses of 35 mcg of inactivated SARS-CoV-2 virus with alum adjuvant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5ml Saline (0.9%)
Study: NCT04599504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate (Medication)
Description: Medication will be taken daily in pill form.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be inactive and taken daily in pill form.
Study: NCT06584357

Intervention type: OTHER
Intervention: Biomarker Data Collection
Description: During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of AD. Some of the samples will be stored for future analysis.

Intervention type: OTHER
Intervention: Biomarker Data Collection
Description: During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of AD. Some of the samples will be stored for future analysis.

Intervention type: OTHER
Intervention: Biomarker Data Collection
Description: During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of AD. Some of the samples will be stored for future analysis.

Intervention type: RADIATION
Intervention: MK6240
Description: Each participant will be assessed using either one of two radioactive tau PET tracers: Flortaucipir or MK6240. Flortaucipir is FDA approved while MK6240 is not and is being used in this study as an investigational radioactive drug.

Intervention type: RADIATION
Intervention: MK6240
Description: Each participant will be assessed using either one of two radioactive tau PET tracers: Flortaucipir or MK6240. Flortaucipir is FDA approved while MK6240 is not and is being used in this study as an investigational radioactive drug.

Intervention type: RADIATION
Intervention: MK6240
Description: Each participant will be assessed using either one of two radioactive tau PET tracers: Flortaucipir or MK6240. Flortaucipir is FDA approved while MK6240 is not and is being used in this study as an investigational radioactive drug.
Study: NCT04953559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active cTBS
Description: Active continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active cTBS
Description: Active continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham cTBS
Description: Sham continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham cTBS
Description: Sham continuous theta burst (cTBS) transcranial magnetic stimulation (TMS)
Study: NCT05448105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Diabetes Care (MDC) Mobile
Description: My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate and tailored diabetes self-care information.
Study: NCT06150274

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Balloon Mitral Valvulotomy
Description: Stenotic mitral valve will be dilated to open the commissures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Balloon Mitral Valvulotomy
Description: Stenotic mitral valve will be dilated to open the commissures
Study: NCT05477563

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX001
Description: Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan.
Study: NCT04750564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreEStim
Description: BreEStim will applied for 10 to 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EStim
Description: EStim will applied for 10 to 20 minutes.
Study: NCT06328439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANS014004
Description: Specification: 7.5mg; 30mg QD Oral
Study: NCT05549596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceragem Master V6 Traction
Description: Ceragem Master V6 Traction for L2\~L3

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy with standard traction device
Description: Physical therapy with standard traction device
Study: NCT05988372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine
Description: Surufatinib:250mg orally once a day for 3 weeks(3 weeks 1 cycle) Serplulimab:4.5mg/Kg by intravenous infusions on day1 every 3 weeks Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-paclitaxel + Gemcitabine
Description: Albumin-paclitaxel:125mg/m2 by intravenous infusions on day1 and 8 every 3 weeks Gemcitabine:1000mg/m2 by intravenous infusions on day1 and 8 every 3 weeks
Study: NCT06138197

Intervention type: PROCEDURE
Intervention: Robotic-assisted hysterectomy
Description: Robotic-assisted hysterectomy following usual surgical technique

Intervention type: PROCEDURE
Intervention: Robotic-assisted hysterectomy
Description: Robotic-assisted hysterectomy following usual surgical technique

Intervention type: PROCEDURE
Intervention: Robotic-assisted hysterectomy
Description: Robotic-assisted hysterectomy following usual surgical technique
Study: NCT05424497

Intervention type: OTHER
Intervention: Vignettes
Description: Presenting vignettes with fictive cases

Intervention type: OTHER
Intervention: Vignettes
Description: Presenting vignettes with fictive cases

Intervention type: OTHER
Intervention: Vignettes
Description: Presenting vignettes with fictive cases

Intervention type: OTHER
Intervention: Vignettes
Description: Presenting vignettes with fictive cases
Study: NCT04705701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Renal replacement therapy is considered standard of care for end stage renal disease patients for clearing the blood and also helping with volume optimization, has different modalities, in our study we are using intermittent hemodialysis.
Study: NCT04692987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision-aid video
Description: Decision-aid video will be developed to disseminate knowledge and to raise awareness on colorectal cancer screening
Study: NCT05854641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stempeucel®
Description: • Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
Study: NCT05600686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Given IV
Study: NCT04659005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-led decision counseling
Description: Provide education, tailored information, decision support, and psychosocial support regarding hepatocellular carcinoma screening

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care provided by the hospital, including one-page written education information about diet, medications, and daily exercises
Study: NCT05600686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV